Cobalamin and folate status predicts mental development scores in North Indian children 12-18 mo of age.

What Was Tested

Researchers studied Cyanocobalamin (Vitamin B12) in this randomized controlled trial publication.

The objective was to measure the association of plasma concentrations of folate, cobalamin, total homocysteine, and methylmalonic acid with cognitive performance at 2 occasions, 4 mo apart, in North Indian children aged 12-18 mo.

Bayley Scales of Infant Development II were used to assess cognition.

Why It Was Studied

Micronutrient deficiencies can affect cognitive function.

Many young children in low- and middle-income countries have inadequate cobalamin (vitamin B-12) status.

Who Took Part

PubMed indexes the participants as infants, both men and women.

In multiple regression models adjusted for several potential confounders, the researchers measured the association between biomarkers for folate and cobalamin status and psychomotor or mental development scores on the day of blood sampling and 4 mo thereafter.

How the Study Was Run

The researchers set it up as a randomized study.

Because people in this Cyanocobalamin (Vitamin B12) study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

What Was Measured

Topics PubMed links to this paper include Biomarkers, Child Development, Cognition Disorders, Cohort Studies, Developmental Disabilities, Folic Acid and Folic Acid Deficiency.

What This Means in Plain Language

The paper is a randomized study of Cyanocobalamin (Vitamin B12).

The abstract goes on to report its results in about 6 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 2013 (The American journal of clinical nutrition), a journal based in United States.

More context: the Cyanocobalamin (Vitamin B12) compound page, all human trials.